# BioAtla, Inc.: overview BCAB · OTC · CIK 1826892 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bcab.md) · [Financials](/companies/bcab/financials.md) · [Filings](/companies/bcab/filings.md) · [Insiders](/companies/bcab/insiders.md) Latest reported revenue: [$0](/filings/0000950170-23-060389.md) for Q3 FY2023, three months to 2023-09-30, from the 10-Q filed Nov 7, 2023 (XBRL us-gaap:Revenues, accession 0000950170-23-060389). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.22)](/filings/0001193125-25-280435.md) | not reported | [(13.16)](/filings/0001193125-26-226631.md) | [(15.99)](/filings/0001193125-26-349542.md) | [(0.27)](/filings/0001193125-25-280435.md) | not reported | [(4.22)](/filings/0001193125-26-226631.md) | [0.27](/filings/0001193125-26-349542.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [300](/filings/0000950170-23-009551.md) | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(32146.7%)](/filings/0000950170-23-009551.md) | not reported | not reported | not reported | not reported | | Net margin | % | [(31800.7%)](/filings/0000950170-23-009551.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.76)](/filings/0000950170-23-009551.md) | [(2.74)](/filings/0000950170-24-036548.md) | [(2.58)](/filings/0000950170-25-046217.md) | [(1.44)](/filings/0001193125-26-134499.md) | [(1.01)](/filings/0001193125-26-134499.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bcab/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $292.4k | 70,616 | | New +70,616 | | [Lido Advisors, LLC](/funds/1650150.md) | 2026-06-30 | $69.0k | 16,656 | | New +16,656 | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $68.0k | 16,432 | | New +16,432 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $53.1k | 12,819 | | New +12,819 | | [DEUTSCHE BANK AG\\](/funds/948046.md) | 2026-06-30 | $43.7k | 10,556 | | New +10,556 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $39.8k | 9,616 | | New +9,616 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $37.9k | 9,164 | | New +9,164 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $25.7k | 6,201 | | New +6,201 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $19.6k | 4,730 | | New +4,730 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $4.6k | 1,108 | | New +1,108 | ## Recent filings [All 505 filings](/companies/bcab/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 21:42 ET | [S-1](/filings/0001539497-26-002711.md) | Registration statement | 0001539497-26-002711 | | 2026-10-20 | 21:33 ET | [8-K](/filings/0001193125-26-425553.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-425553 | | 2026-09-29 | 17:16 ET | [8-K](/filings/0001193125-26-407817.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-407817 | | 2026-08-28 | 08:01 ET | [8-K](/filings/0001539497-26-002373.md) | 3.01 Delisting notice | 0001539497-26-002373 | | 2026-08-13 | 17:00 ET | [10-Q](/filings/0001193125-26-349542.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349542 | | 2026-07-16 | 16:12 ET | [8-K](/filings/0001193125-26-306117.md) | 5.07 Shareholder vote results | 0001193125-26-306117 | | 2026-06-03 | 16:07 ET | [DEF 14A](/filings/0001193125-26-255422.md) | Proxy statement, period 2026-06-03 | 0001193125-26-255422 | | 2026-05-15 | 16:05 ET | [10-Q](/filings/0001193125-26-226631.md) | Quarterly report, period 2026-03-31 | 0001193125-26-226631 | | 2026-04-29 | 16:05 ET | [10-K/A](/filings/0001193125-26-191493.md) | Annual report, amended, period 2025-12-31 | 0001193125-26-191493 | | 2026-04-02 | 16:05 ET | [8-K](/filings/0001193125-26-140053.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-140053 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-134499.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1826892 - Tickers: BCAB - Exchange: OTC - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 06:15 ET. No prices; not investment advice.